Iopofosine I 131 achieved 79% major response in BTK inhibitor-refractory Waldenström macroglobulinemia patients in Phase 2b trial data.

Vanda's tasimelteon meets Phase III endpoint in delayed sleep-wake disorder, advancing 60% of patients' sleep onset by 30+ minutes...

AbbVie's zumilokibart met all primary endpoints in Phase 2 atopic dermatitis testing, showing rapid skin and itch improvement with...

Plinabulin earns FDA Fast Track Status for advanced NSCLC after ICI failure, advancing BeyondSpring's DUBLIN-4 Phase 3 trial in...

AB Science buried a five-inspector "for cause" GCP inspection inside a financial calendar update. Masitinib's ALS trial and three...

AGENT framework achieves 100% mRNA bioactivity after 2+ months at 37°C, forcing a rethink of cold-chain assumptions in vaccine...

FDA Single IRB Rule for multisite trials advances to final rule status in December 2026, ending parallel IRB review...

Novo Nordisk licenses oral GLP-1/GIP dual agonist HRS-1596 from Hengrui for $300M upfront, with potential $2.6B in milestone payments.

Keros Therapeutics enrolls first patient in Phase 2 rinvatercept DMD trial to evaluate myostatin/activin inhibition for Duchenne muscular dystrophy.

CIRM awards Fate Therapeutics $15M to advance FT819 lupus nephritis trial, testing allogeneic CAR T-cell therapy in patients failing...